# Overview

This document presents findings regarding the **Gal-9** antibody, **HFB9**, and its role in immune regulation and cancer therapy.

## Mechanisms and Efficacy

- Gal-9 is implicated in **immune suppression** within the tumor microenvironment, affecting responses in patients with **Acute Myeloid Leukemia (AML)**.
- Monoclonal antibodies targeting **Gal-9** have shown sustained immunological responses.
- Evidence suggests these antibodies can potentially reverse immune suppression, making them significant for cancer therapy.

### Experimental Results

- **PBMCs** from healthy donors were analyzed over 30 days, revealing distinct interactions with **Gal-9** and **2-9 HFB**.
- Binding affinity studies indicated a high level of reactivity between **humanized anti-Gal-9 antibody** and tumor expressions.
- Cytotoxic effects and efficacy were demonstrated in **syngeneic tumor models** after administration of HFB9-2.

## Antitumor Activity

- **In vivo evaluations** showed the potential of **HFB9-2** as an anti-tumor agent in various cancer models.
- Significant anti-tumor effects were observed with combinations of **anti-Gal-9 treatments**, achieving complete tumor rejection in a substantial percentage of tested subjects.

## Conclusion

- The **HFB9-2 neutralizing antibody** demonstrated:
    - Sub-nanomolar affinity for **Gal-9**.
    - Cross-reactivity to **mouse and monkey** orthologs.
    - Favorable pharmacokinetics and developability.
    - Key inhibitory effects on **Th1 apoptosis** and **Treg expansion**.
- The observed levels of **Gal-9** in **AML patients** suggest a potential therapeutic target to counter immunosuppression and enhance the efficacy of cancer treatments.

## Contact Information
For additional inquiries or information regarding the study, please reach out via email to **g.margallducos@hifibio.com**.